Respiratory Inhalers Market 2028: Research Methodology Focuses on Exploring Major Factors Influencing the Industry Development

Respiratory inhalers can be classified into various types according to their mechanism of action and usage. They are broadly classified into two categories as therapeutic and prophylactic, based on their chemical structure and mechanism of action. Therapeutic Respiratory Inhalers are used for treating acute respiratory conditions such as allergies, asthma, COPD, rhinitis, sinusitis, viral respiratory infection, pneumonia, irritations of the respiratory tract caused due to exposure to dust and other airborne irritants, including pollens, molds, and animal dander, inhalers for preventing short-term complications of respiratory disease.

Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/227

They are also used to control chronic obstructive pulmonary disease (COPD) in people with emphysema. Respiratory prophylactics are used for preventing or controlling complications of diseases that are associated with obstruction of the respiratory tract, such as tuberculosis, bronchitis, pneumonia, and emphysema.

Market Dynamics

Increasing prevalence of asthma is expected to propel growth of the global respiratory inhalers market. For instance, According to The Global Asthma Report 2018, around 300 million people have asthma worldwide, and the number is expected to reach 100 million by 2025. Moreover, initiatives to boost adoption of dry powder inhalers is also expected to aid in growth of the market. For instance, in September 2018, researchers from University of Helsinki, Finland, reported investigation of non-verbal, demonstrational videos as a method of teaching inhaler naïve individuals how to use a dry powder inhaler.

Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the global respiratory inhalers market. For instance, globally, as of 4:35pm CET, 27 January 2021, there have been 99,864,391 confirmed cases of COVID-19, including 2,149,700 deaths, reported to the World Health Organization. Moreover, launch of solutions to track usage pattern of metered-dose inhalers is also expected to aid in growth of the market. For instance, in November 2019, Lupin Ltd. launched a device – Adhero – to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases.

Competitive Analysis

Major players operating in the global respiratory inhalers market include, AstraZeneca plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.

Major players operating in the global respiratory inhalers market are focused on approval and launch of new products to expand their product portfolio. For instance, in April 2019, Glenmark Pharmaceuticals launched two new steroid inhalers that include Soprobec (beclometasone), a metered-dose aerosol inhaler, and Stalpex (salmeterol/fluticasone), a breath-actuated inhaler. Similarly, in April 2019, Cipla Ltd. launched Niveoli, an extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, which can be used for the treatment of asthma and COPD.

Buy Now with Discount for Premium Report : – https://www.coherentmarketinsights.com/promo/buynow/227

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sale@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.